BioBlog Weekly oncology

Cancer Drug Research and Pricing and More

IP Blog | Dave Melin | July 16, 2017

In this week’s BioBlog we look at recent happenings in the development and research of cancer drugs, cancer drug price increases, a push by democrats for single-payer healthcare, new Alzheimer disease research, and the ongoing opioid prescription crisis in the US. Lung, Liver and Stomach Cancers Kill a Million Chinese a Year; Big Pharma Responds […]

Read Full Post »


BioBlog Weekly oncology

Exciting New Research and Treatments for Leukemia

IP Blog | Dave Melin | July 9, 2017

In this week’s BioBlog we look into several new studies for Acute Myeloid Leukemia, along with promising new drugs to help treat and reduce relapse occurrence in AML patients. Stem-Cell Researchers Solve Mystery of Relapse in Acute Myeloid Leukemia Scientists have identified a specific type of stem-cell that is present at the time of diagnosis […]

Read Full Post »


BioBlog Weekly oncology

Drug Pricing, MACRA Exemptions, Healthcare Exchange Profitability, and Artificial Intelligence in Healthcare

IP Blog | Dave Melin | July 2, 2017

In this week’s BioBlog we look at the latest developments in the ongoing drug pricing battle, another group of providers receiving exemption from the MACRA requirements, and look into the future of using artificial intelligence in healthcare. Draft Order on Drug Prices Proposes Easing Regulations The New York Times reports that a draft of an […]

Read Full Post »


BioBlog Weekly oncology

In’s and Out’s of the Senate Healthcare Bill

IP Blog | Dave Melin | June 25, 2017

This week’s BioBlog explores various aspects of the Senate’s Healthcare Bill. Senate Republicans Reveal Long-Awaited Affordable Care Act Repeal Bill In this article, NPR highlights the major changes that would occur if the newly released senate healthcare bill passes. CHART: Who Wins, Who Loses With Senate Health Care Bill The chart in this article highlights […]

Read Full Post »


BioBlog Weekly oncology

New Investments, Sharpless Appointment, New Cancer Treatment Discoveries

IP Blog | Dave Melin | June 18, 2017

In this week’s BioBlog we learn more about Google’s recent investments in the pharmaceutical and medical industry, Cigna’s continued support of Omada Health, Trump’s recent appointing of Sharpless, and potential new treatments for cancer. Google Is Ramping Up Pharma Activity Google continues to expand their investments in the pharmaceutical field this year, continuing on recent indications […]

Read Full Post »


BioBlog Weekly oncology

BioBlog ASCO Recap Edition

IP Blog | Dave Melin | June 7, 2017

This special edition of the BioBlog outlines the issues, happenings and information relevant to this year’s ASCO Annual Meeting held June 1 – 5 in Chicago. Cancer Drug Prices Could Double or Triple Thanks to This Popular but Unproven Drug Trend This online article from MarketWatch outlines the “safety concerns and issues of price hang above […]

Read Full Post »


BioBlog Weekly oncology

Cancer Research Funding, CancerLinQ, Superbug Treatment, ADHD Drugs, Big Pharma, Medicaid Growth, and the Opioid Crisis

IP Blog | Dave Melin | June 5, 2017

In this week’s BioBlog we look at recent developments across the healthcare field, including cancer research funding and data tracking of cancer treatments, a revamped antibiotic to combat superbugs, ADHD medication, Big Pharma, Medicaid enrollment, and the opioid crisis. As Government-Funded Cancer Research Sags, Scientists Fear U.S. Is ‘Losing Its Edge’ Looking ahead to significant […]

Read Full Post »


BioBlog Weekly oncology

Advancements in the Treatment and Prevention of Various Types of Cancer

IP Blog | Dave Melin | May 29, 2017

In this week’s BioBlog, we look at recent advancements in cancer drugs, treatments, and ways to cut risks of getting cancer. Brigatinib First Drug to Offer Over 1-Year Control of ALK-Positive Lung Cancer Post-Crizotinib Promising new findings show that the drug, Brigatinib, has a 54 percent response rate in cancers that didn’t respond to Crizotinib. […]

Read Full Post »


BioBlog Weekly oncology

Drug Pricing, MACRA Requirement, and Alternative Payment Models

IP Blog | Dave Melin | May 21, 2017

In this week’s BioBlog we read about recent developments in the ongoing fight to lower drug prices, ASCO’s new payment model alternative, and more physicians being excluded from the MACRA requirements. The White House Budget Director Dropped a Hint About How Trump Could Bring Drug Prices Down Mick Mulvaney suggested that it is possible that […]

Read Full Post »


BioBlog Weekly oncology

Obamacare, Trumpcare, Uninsured with Cancer, Research Efforts

IP Blog | Dave Melin | May 14, 2017

In this week’s BioBlog we look at the fallout from the uncertain future of Obamacare, Trumpcare’s position on pre-existing conditions, the challenge of diagnosing cancer early in patients without insurance, and new research to try and detect cancer earlier. Obamacare Premiums Rise as Insurers Fret Over Law’s Shaky Future With the uncertain future of Obamacare […]

Read Full Post »


BioBlog Weekly oncology

Trumpcare, Value Frameworks, GA Firefighter Cancer Bill Signed

IP Blog | Dave Melin | May 8, 2017

In this week’s BioBlog we look at the AHCA bill contents as it was passed by the House, the need to revamp value frameworks to make them a useful tool, as well as an exciting new bill passed in Georgia to get firefighters covered for various types of cancer. House Gives Green Light to Amended […]

Read Full Post »


BioBlog Weekly oncology

Drug Costs, Federal Funding, New Partnerships, and Supreme Court Hearings

IP Blog | Dave Melin | April 30, 2017

In this week’s BioBlog we explore the ending of a major contract between Express Scripts and Anthem, the continued battle over drug costs, an Upcoming meeting between the Trump administration and drug companies, a new partnership between Walgreens and Prime, and a highly anticipated hearing in the Supreme Court. A Huge Pharma Middleman Just Lost […]

Read Full Post »


BioBlog Weekly oncology

Research Yields New Methods of Attack, Diagnosis, and Mysteries of Breast Cancer

IP Blog | Dave Melin | April 23, 2017

The articles in this week’s BioBlog explore new research and initiatives in breast cancer. Scientists Identify New Way of Attacking Breast Cancer Scientists have discovered a new way to attack breast cancer by blocking a protein that has been shown to increase tumor growth. The Impostor Cell Line That Set Back Breast Cancer Research It […]

Read Full Post »


BioBlog Weekly oncology

Cancer Moonshot, Cancer Funding, Genome Mapping

IP Blog | Dave Melin | April 16, 2017

In this week’s BioBlog, we learn about recent progress in the Cancer Moonshot initiative, potential cuts to cancer research funding, as well as a proposed shift in genome mapping. A Cancer ‘Moonshot’ In this article we learn how Bloomberg–Kimmel Institute for Cancer Immunotherapy is helping Johns Hopkins further their research in immunotherapy. Biden Gives Update on Cancer […]

Read Full Post »


BioBlog Weekly oncology

Cancer Drug Costs and Development

IP Blog | Dave Melin | April 9, 2017

In this week’s BioBlog we examine the process to develop and bring new cancer drugs to market. The new drugs come at high price, creating a lot of debate and chatter on the best way to control and lower these prices. The Cost of Cancer: New Drugs Show Success at a Steep Price Immunotherapy drugs continue […]

Read Full Post »


BioBlog Weekly oncology

IP Blog | Dave Melin | April 2, 2017

This week’s BioBlog features articles about Immunotherapy Biomarkers, Trump Vows to Explode ACA, Cancer and Immunity, the Benefits of Early Palliative Care and more. Diving Deeper Into Cancer Immunotherapy Biomarkers Looking at the future of immunotherapy one main obstacle remains: determining which patients will benefit from it. Affordable Care Act Remains ‘Law of the Land,’ […]

Read Full Post »


BioBlog Weekly oncology

AHCA Pulled, End of Life Models, Biosimilars, MACRA, ASCO Lifting COI Restrictions

IP Blog | Dave Melin | March 26, 2017

In this week’s BioBlog we look at the American Health Care Act being pulled, new research in various end of life models, the use of biosimilars to lower the cost of drug therapy, MACRA implementation, and ASCO removing conflict of interest restrictions on researchers. House Republicans Pull Health Care Bill Since they didn’t have the votes […]

Read Full Post »


BioBlog Weekly oncology

American Health Care Act, Nominations and Confirmations, ASCO Special Awards

IP Blog | Dave Melin | March 19, 2017

In this week’s BioBlog we look at the new details and projections for the American Health Care Act, the confirmation of Seema Verma and the nomination of Dr. Scott Gottlieb for FDA commissioner. ASCO has also announced this year’s recipients of the ASCO Special Awards. CBO: Republican Healthcare Bill Would Reduce Federal Deficit—but Millions Fewer […]

Read Full Post »


BioBlog Weekly oncology

ACA Repeal, CancerLinQ, and State of Cancer Care in America Report

IP Blog | Dave Melin | March 12, 2017

This week’s BioBlog focuses on the newly unveiled bill to repeal and replace Obamacare, a newly formed CancerLinQ ambassadors program, and the upcoming release of the annual State of Cancer in America report. Republicans Finally Ready to Reveal ACA Repeal and Replace Plan but Opposition is Likely This week republicans unveiled their new plan to […]

Read Full Post »


BioBlog Weekly oncology

CancerLinQ, Cancer Moonshot Funding Opportunities, AI, and More

IP Blog | Dave Melin | March 5, 2017

This week’s BioBlog is stocked with current articles from around the web that relate to oncology, big data, and innovative health care. CancerLinQ Partners with Premier Radiation Oncology Society This new partnership promises to bring radiation oncology expertise to help improve cancer care. NCI Announced New Funding Opportunities Related to Cancer Moonshot The National Cancer Institute […]

Read Full Post »


BioBlog Weekly oncology

Drug Costs, Patient-Generated Health Data, ACA Repeal, Multigene Testing, and Cancer Policy

IP Blog | Dave Melin | February 26, 2017

In this week’s BioBlog we look at how difficult it is for cancer patients to afford their medications and the difficult choices they face, the outlook for hospital in the potential ACA repeal and more. Cancer Survivors Skip Prescription Drugs Due to Cost: Study New research shows that cancer patients often skip doses or look […]

Read Full Post »


BioBlog Weekly oncology

Tom Price Confirmed, Humana Exit, Cancer Moonshot, and Cooling Caps

IP Blog | Dave Melin | February 19, 2017

In this week’s BioBlog we look at the confirmation of Tom Price, the exit of Humana in the exchanges, new developments in the Cancer Moonshot initiative, and the use of cooling caps during chemotherapy. ASCO Congratulates Rep. Tom Price on Confirmation as Secretary of Health and Human Services ASCO is looking forward to working with […]

Read Full Post »


BioBlog Weekly oncology

Reducing Drug Costs, Value-Based Care, and Precision Medicine

IP Blog | Dave Melin | February 12, 2017

In this week’s BioBlog we learn about new and continued efforts being made to reduce drug costs, the continued effort toward value-based care and evaluating treatment effectiveness, as well as the obstacle of the high costs of cancer treatment. Report Commissioned by COA Explores “Murky” World of Pharmacy DIR Fees In this article we look […]

Read Full Post »


BioBlog Weekly oncology

Kaput Acquisitions, Cancer Drugs and Quality Measures

IP Blog | Dave Melin | February 5, 2017

This week’s BioBlog outlines the Anthem Cigna deal,  several articles on increased prices of cancer drugs, and suggestions to improve oncology quality measures. Anthem’s Cigna Deal Is All but Kaput, and That May Be Good News for Blues Plans It seems likely that Anthem’s plan to buy Cigna will not be approved, since it would substantially […]

Read Full Post »


BioBlog Weekly oncology

2017 Proving to Be Full of Changes in Cancer Healthcare

IP Blog | Dave Melin | January 29, 2017

This week’s BioBlog contains a few of the many articles that share the changes, innovations, and forecasts that 2017 is heralding. ION Solutions to Provide Patient Engagement Technology to its Nationwide Oncology Network with HealthGrid This article reports on how HealthGrid technology will allow ION members who dispense and administer oral chemotherapy to connect with patients […]

Read Full Post »


BioBlog Weekly oncology

Drug Formulary, Quality Reporting, Prescription Database, Pharmaceutical Companies Sold, and Drug Rebates

IP Blog | Dave Melin | January 22, 2017

In this week’s BioBlog we look at a new drug formulary, the new MACRA fact sheets, and the development of a universal prescription database. Also in the news the sale of pharmaceutical companies, and drug rebates that health plan providers receive. New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials This week […]

Read Full Post »


BioBlog Weekly oncology

Cancer Moonshot, Drug Pricing, ACA Repeal, and Pharmaceutical Company Acquisitions

IP Blog | Dave Melin | January 15, 2017

This week’s BioBlog focuses on VP Biden’s plans after he leaves office, pharmaceutical company acquisitions, the drive to repeal and replace the ACA, and the continued battle over drug costs. At San Francisco Event, Biden Vows to Make Fighting Cancer His Cause At an event in San Francisco, VP Biden reiterated his intentions to continue his […]

Read Full Post »


BioBlog Weekly oncology

Obamacare Repeal, Drug Prices, Cancer Research Advances

IP Blog | Dave Melin | January 8, 2017

In this week’s Bio Blog we look at the road to repealing and replacing ObamaCare, research advances in how cancer spreads, and Biden’s plans to continue working on cancer issues when he leaves office. U.S. Republican Senator Introduces Obamacare Repeal Resolution The Senate budget committee chairman, Mike Enzi, introduced a resolution to repeal Obamacare on the […]

Read Full Post »


BioBlog Weekly oncology

Cancer Research, Clinical Trials, and Drug Costs

IP Blog | Dave Melin | January 2, 2017

In this week’s BioBlog we look at advancements in cancer research and clinical trials, and the high costs of cancer drugs limiting the availability of it to patients. TSU Cancer Research Aims to Reduce Disparities A current research project at Tennessee State University is studying what creates higher cancer rates in specific groups compared to […]

Read Full Post »


BioBlog Weekly oncology

Cancer Drug Costs, Part B Demo, and Value-Base Care

IP Blog | Dave Melin | December 26, 2016

In this week’s BioBlog we look at the cost and regulation of cancer drugs, the outlook for value-based care in the new administration, and the Part B Demo. In Closely Watched Case, Colombia Cuts the Price of a Novartis Cancer Drug by 44 Percent The Colombian government moved to reduce the cost of the cancer […]

Read Full Post »